New injectables don't surprise the owners who watch the pipeline. They surprise everyone else — usually in the form of a rep walking in to announce a launch that's already underway, a competitor advertising a product you've never heard of, or a patient asking for something by name. By then the most valuable part of a new entrant's arrival — the early competitive window — is half over, and you're reacting from behind instead of positioning ahead. Reading the pipeline isn't about clinical early-adoption for its own sake. It's about being the practice that was ready when the market moved.
Trends & Forecast
Injectable Pipeline Watch: How to Read What's Heading for FDA Decisions Before It Hits Your Market
New toxins and fillers don't surprise the owners who watch the pipeline. Knowing what's coming — and reading the launch window correctly — is the difference between exploiting a new entrant and being disrupted by it.
